Drug intelligence / Profile preview

IMB1004

Development stage: Preclinical
Lead developer: IMIDomics

Overview

IMB1004 is a preclinical-stage biologic candidate being developed by IMIDomics for the treatment of immune-mediated inflammatory diseases (IMIDs), including ulcerative colitis, Crohn's disease, and systemic lupus erythematosus. The drug target was identified through IMIDomics' proprietary Clinical Discovery Engine™, a multidimensional, data-driven platform that integrates clinical and molecular data to uncover underlying disease mechanisms. In collaboration with the University of Barcelona and its IP transfer foundation, Fundació Bosch i Gimpera, IMIDomics is utilizing specialized biologics discovery expertise to validate and advance IMB1004 through the preclinical pipeline.

Beyond the preview

Go deeper on IMB1004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMB1004.

Explore the full profile